Wang Qi, Zhang Jiansheng, Li Kunpeng, Miao Xin, Wang Yuhan, Zhang Linlin
School of Medical and Health Engineering in Changzhou University, No. 21, Gehu Middle Road, Wujin District, Changzhou City, Jiangsu Province, 213164, PR China.
The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People's Hospital, No. 2, Xindu West Road, Yandu District, Yancheng City, Jiangsu Province, 224001, PR China; Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, PR China.
Res Social Adm Pharm. 2025 Oct;21(10):753-764. doi: 10.1016/j.sapharm.2025.05.011. Epub 2025 May 21.
Currently there is still no network meta-analysis of the effectiveness of different medication management measures for older adults with chronic diseases and polypharmacy. Therefore, a network meta-analysis was conducted to assess the impact of different management measures on older patients with chronic diseases and polypharmacy.
Multiple databases, including PubMed, Web of Science, Embase, Cochrane Library, and CINAHL, were searched from inception to February 28, 2024. The inclusion criteria were the following: Population: older adults with chronic diseases who required long-term polypharmacy; Intervention: medication management measures; Comparison: usual care or a blank control; Outcome: 1) number of medications; 2) self-rated quality of life; 3) mortality, hospital admission rate, and fall rate; Study design: randomized controlled trials (RCTs).Methodological quality was assessed by version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2). In this study, R4.3.3 and Stata 17.0 were used to generate a flow diagram for network meta-analysis (NMA).
A total of 25 RCTs were included in the study. They involved 15794 patients and 7 medication management measures below: medication review (MR), medication record (MRD), deprescribing interventions (DI), medication review with follow-up (MRF), medicine electronic decision support tool (EDS), medication therapy management (MTM), and pharmacotherapy consultation and education (CE). The league table results showed that DI was superior to the control in improving prescription appropriateness (MD = -0.90, 95 % CI: -1.83,-0.11, P < 0.05), and MRF was superior to DI in decreasing the hospital admission rate (RR = 0.26, 95 % CI: 0.06, 0.93, P < 0.05). The surface under the cumulative ranking curve (SUCRA) values showed that DI (88.30 %) was the most promising management measure to improve prescription appropriateness. MRF was the most promising management measure to improve self-rated quality of life (93.04 %) and reduce the hospital admission rate (96.41 %). CE was the most promising management measure to reduce mortality (68.69 %). EDS was the most promising management measure to reduce the fall rate (69.46 %). The results of cluster analysis showed that MR was the most promising management measure to evaluate all outcome measures.
Currently, for polypharmacy management in older patients with chronic diseases, DI, MRF, CE, and EDS are the most promising management measures to improve the appropriateness of prescribing, improve self-rated quality of life and reduce the hospital admission rate, reduce mortality, and reduce the fall rate, respectively. However, this conclusion needs to be confirmed by more large-sample, multicenter RCTs due to the limitations of existing studies.
The registration number was CRD42024540141.
目前尚无针对患有慢性病且用药复杂的老年人不同药物管理措施有效性的网络荟萃分析。因此,开展了一项网络荟萃分析,以评估不同管理措施对患有慢性病且用药复杂的老年患者的影响。
检索多个数据库,包括PubMed、Web of Science、Embase、Cochrane图书馆和CINAHL,检索时间从建库至2024年2月28日。纳入标准如下:人群:患有慢性病且需要长期多种药物治疗的老年人;干预措施:药物管理措施;对照:常规护理或空白对照;结局指标:1)用药数量;2)自评生活质量;3)死亡率、住院率和跌倒率;研究设计:随机对照试验(RCT)。采用Cochrane随机试验偏倚风险工具第2版(RoB 2)评估方法学质量。本研究使用R4.3.3和Stata 17.0生成网络荟萃分析(NMA)的流程图。
本研究共纳入25项RCT。这些研究涉及15794例患者以及以下7种药物管理措施:药物审查(MR)、用药记录(MRD)、减药干预(DI)、随访药物审查(MRF)、药物电子决策支持工具(EDS)、药物治疗管理(MTM)以及药物治疗咨询与教育(CE)。排行榜结果显示,DI在改善处方合理性方面优于对照组(MD = -0.90,95%CI:-1.83,-0.11,P < 0.05),而MRF在降低住院率方面优于DI(RR = 0.26,95%CI:0.06,0.93,P < 0.05)。累积排序曲线下面积(SUCRA)值表明,DI(88.30%)是改善处方合理性最有前景管理措施。MRF是改善自评生活质量(93.04%)和降低住院率(96.41%)最有前景管理措施。CE是降低死亡率最有前景管理措施(68.69%)。EDS是降低跌倒率最有前景管理措施(69.46%)。聚类分析结果显示,MR是评估所有结局指标最有前景管理措施。
目前,对于患有慢性病的老年患者的多重用药管理,DI、MRF、CE和EDS分别是改善处方合理性、改善自评生活质量、降低住院率、降低死亡率和降低跌倒率最有前景管理措施。然而,由于现有研究的局限性,这一结论需要更多大样本、多中心RCT予以证实。
注册号为CRD42024540141。